Psoriatic Arthritis Therapeutics Market Size in 7MM is expected to grow by 2034, estimates DelveInsight

DelveInsight's 'Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast - 2034' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the psoriatic arthritis therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover Key Insights into the Psoriatic Arthritis Market with DelveInsight's In-Depth Report @ Psoriatic Arthritis Market Size [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from Psoriatic Arthritis Market Research Report

* In November 2024:- AbbVie- A Phase 3, Randomized, Double-Blind Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE 2).
* According to DelveInsight's analysis, Psoriatic Arthritis was observed to affect females more frequently than males. In 2023, females accounted for approximately 15% more PsA cases compared to males.
* DelveInsight's analysis indicates that in 2023, the majority of Psoriatic Arthritis cases were of moderate severity, comprising approximately 60% of cases, followed by severe and mild forms.
* In the US in 2023, the age group 50-59 years had the highest prevalence of Psoriatic Arthritis, while the 18-29 age group had the lowest number of cases.
* According to DelveInsight's analysis, in 2023, Germany had the highest number of Psoriatic Arthritis cases among the EU4 countries and the UK, while Spain reported the lowest.
* The National Psoriatic Foundation reports that approximately 1 in 3 individuals, or 30%, with psoriasis develop Psoriatic Arthritis, affecting up to 2.4 million Americans. PsA can occur at any age.
* According to the study by Brent et al. (2024), the prevalence of psoriatic arthritis among individuals with psoriasis was 1.7% at 5 years, 3.1% at 10 years, 5.1% at 20 years, and 20.5% at 30 years. Overall, the prevalence of psoriatic arthritis in psoriasis patients is 19.7%, with 21.6% in adults and 3.3% in children.
* The leading Psoriatic Arthritis Companies such as AbbVie, Amgen, Johnson & Johnson, Bristol, Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, and UCB Biosciences Inc., and others.
* Promising Psoriatic Arthritis Therapies such as NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg , and others.

Stay ahead in the Psoriatic Arthritis Therapeutics Market with DelveInsight's Strategic Report @ Psoriatic Arthritis Market Outlook [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Psoriatic Arthritis Epidemiology Segmentation in the 7MM

* Psoriatic Arthritis prevalent cases
* Psoriatic Arthritis diagnosed cases
* Psoriatic Arthritis gender-specific cases
* Psoriatic Arthritis age-specific cases
* Psoriatic Arthritis severity-specific cases

Download the report to understand which factors are driving Psoriatic Arthritis epidemiology trends @ Psoriatic Arthritis Prevalence [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Psoriatic Arthritis Emerging Drugs

* Bimekizumab (UCB Biopharma) is an investigational, humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes. IL-17F has overlapping biology with IL-17A and drives inflammation independently of IL-17A.
* Tildrakizumab (Sun Pharmaceutical) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in the US.

Psoriatic Arthritis Drugs Market

The Psoriatic Arthritis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Psoriatic Arthritis signaling in Psoriatic Arthritis are likely to uncover new therapeutic targets and further expand treatment options for patients.

Psoriatic Arthritis Treatment Market Landscape

The Psoriatic Arthritis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Psoriatic Arthritis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

Get In-Depth Knowledge on Psoriatic Arthritis Market Trends and Forecasts with DelveInsight @ Psoriatic Arthritis Treatment Market [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Psoriatic Arthritis Companies

AbbVie, Amgen, Johnson & Johnson, Bristol, Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, and UCB Biosciences Inc., and others.

Scope of the Psoriatic Arthritis Market Report

* Coverage- 7MM
* Study Period- 2020-2034
* Psoriatic Arthritis Companies- AbbVie, Amgen, Johnson & Johnson, Bristol, Myers Squibb Company, Celgene Corporation, Novartis, Eli Lilly and Company, and UCB Biosciences Inc., and others.
* Psoriatic Arthritis Therapies- NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, and others.
* Psoriatic Arthritis Market Dynamics: Psoriatic Arthritis Market Drivers and Barriers
* Psoriatic Arthritis Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight's Comprehensive Psoriatic Arthritis Market Report @ Psoriatic Arthritis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/psoriatic-arthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Psoriatic Arthritis Market Overview at a Glance

4. Executive Summary of Psoriatic Arthritis

5. Disease Background and Overview

6. Epidemiology and Patient Population

7. Patient Journey of Psoriatic Arthritis

8. Marketed Products

9. Emerging Therapies

10. Other Assets

11. Psoriatic Arthritis (PsA): Seven Major Market Analysis

12. SWOT Analysis

13. KOL Views

14. Unmet Needs

15. Market Access

16. Acronyms and Abbreviations

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=psoriatic-arthritis-therapeutics-market-size-in-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage



This release was published on openPR.